- Biotech on the Web - https://biotechontheweb.com -

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Share:
[1] [2] [3] [4]

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide(1)

Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the favorable safety profile of Kesimpta in patients with relapsing forms of multiple sclerosis (RMS)(2)

Baseline serum neurofilament light chain (NfL) levels in the ASCLEPIOS trials demonstrated a prognostic value for disease activity and worsening in all patients, including newly diagnosed, treatment-naïve patients(3)

Kesimpta is the first and only FDA-approved, self-administered, targeted B-cell therapy for adults with RMS(4)

MORE… [5]

Author: Canan Schuman, PharmD/PhD [6]

Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.